Utah Retirement Systems lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 305,062 shares of the biopharmaceutical company’s stock after acquiring an additional 700 shares during the period. Utah Retirement Systems’ holdings in Bristol-Myers Squibb were worth $15,857,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Oregon Public Employees Retirement Fund boosted its stake in Bristol-Myers Squibb by 2,326.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 8,850,072 shares in the last quarter. Winslow Capital Management LLC acquired a new stake in Bristol-Myers Squibb during the third quarter worth $378,839,000. Jennison Associates LLC boosted its stake in Bristol-Myers Squibb by 23.4% during the third quarter. Jennison Associates LLC now owns 21,526,559 shares of the biopharmaceutical company’s stock worth $1,336,369,000 after buying an additional 4,080,245 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd boosted its stake in Bristol-Myers Squibb by 6,090.3% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock worth $214,700,000 after buying an additional 4,063,712 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Bristol-Myers Squibb by 2.4% during the third quarter. BlackRock Inc. now owns 114,573,885 shares of the biopharmaceutical company’s stock worth $7,112,747,000 after buying an additional 2,660,326 shares in the last quarter. Institutional investors and hedge funds own 73.35% of the company’s stock.
Shares of NYSE BMY traded down $0.64 during midday trading on Friday, reaching $49.25. 5,638,534 shares of the company traded hands, compared to its average volume of 20,495,434. The stock has a market cap of $80.88 billion, a PE ratio of 12.37, a PEG ratio of 2.22 and a beta of 0.81. Bristol-Myers Squibb Co has a 12 month low of $44.30 and a 12 month high of $67.44. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the business earned $0.68 earnings per share. Analysts predict that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.33%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
A number of research firms have weighed in on BMY. Credit Suisse Group reiterated a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. BMO Capital Markets lifted their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Friday, November 16th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Tuesday, March 5th. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, November 27th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $59.40.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thestockobserver.com/2019/03/15/bristol-myers-squibb-co-bmy-shares-bought-by-utah-retirement-systems.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: How do investors use RSI to grade stocks?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.